Triallo Logo
  • Home
  • Search
  • Contact

Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty

Triallo

Triallo is a platform that connects patients with life-changing clinical trials. Find hope, access innovative treatments, and contribute to medical breakthroughs.


© 2025 Triallo. All rights reserved.

Privacy PolicyTerms of Service
1-20 of 3,900 trials

Adrenocortical Carcinoma: Mitotane Treatment Study

We are comparing standard mitotane therapy to mitotane combined with chemotherapy for patients at high risk of cancer recurrence after surgery. This study aims to find out which treatment helps patients live longer and maintain a better quality of life.

Adrenocortical Carcinoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Urothelial Cancer: Disitamab Vedotin with Pembrolizumab

We are studying the effects of disitamab vedotin alone or with pembrolizumab in patients with HER2-positive urothelial cancer. This trial aims to see if these treatments can improve outcomes for those with advanced disease.

Bladder CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Hodgkin Lymphoma: A2VD vs. ABVD Treatment Study

We are comparing two treatment options for patients with untreated early-stage Hodgkin lymphoma to see which may improve survival and reduce side effects. This study uses advanced imaging techniques to guide treatment decisions.

Classical Hodgkin LymphomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Acute Heart Failure: Treatment Comparison Study

We are testing different emergency treatments for pulmonary congestion in patients with acute heart failure. The goal is to see which method helps patients feel better faster after they arrive at the hospital.

Acute Heart Failure with Pulmonary Congestion>2 yearsMonitoring phase (IV)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

SPRING Rollover: Follow-Up Study

This study is for participants from the previous SPRING trial to assess ongoing effects and safety of the treatment. We aim to gather more information on its long-term benefits.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Oncology

Alzheimer's Disease and Down Syndrome: ACI-24.060 Study

We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Nalmefene for Reducing Cravings in Behavioral Addictions

We are studying whether nalmefene can help reduce craving intensity in people with behavioral addictions, such as gambling and food addiction, when added to their usual treatment.

Behavioural AddictionConfirmation phase (III)≤5 visitsStandard MedicinesCost Reimbursement

Cholangiocarcinoma: Comparing RFA and PDT Treatments

We are studying whether radiofrequency ablation or photodynamic therapy helps patients with cholangiocarcinoma live longer. We’ll also look at how these treatments affect quality of life and any potential side effects.

Hilar Cholangiocarcinoma>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Corneal Transplantation: Optimized Immunosuppression Study

We are testing new immunosuppressive protocols for patients receiving corneal transplants to see if they can reduce eye pressure and cell loss. We also want to understand patient experiences and the cost-effectiveness of these treatments.

Corneal Graft Failure1-2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

Heart Attack Treatment: The Dan-DAPT Trial

We are testing a tailored blood-thinning strategy for heart attack patients at high bleeding risk. The goal is to see if this approach can lower bleeding without raising the chance of heart problems.

Heart Attack>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Coronary Artery Disease Screening: Heart CT in Type 2 Diabetes

We are studying whether a heart CT scan can help find early signs of heart disease in people with type 2 diabetes. This may lead to better treatment options and improved heart health.

Type 2 DiabetesMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyDiabetologyEndocrinology

FORE-PAIN Trial: Pain Relief Options for Trauma

We are studying whether intranasal and intravenous forms of fentanyl and esketamine can effectively relieve acute traumatic pain. The goal is to see if these options are as safe and satisfying as traditional intravenous fentanyl.

Acute Traumatic PainConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOtolaryngologyPsychiatry

Cardiac AL Amyloidosis: [18F]florbetaben PET Imaging Study

We are evaluating a new imaging technique to improve the diagnosis of cardiac AL amyloidosis in patients. This study will help us understand how well it works compared to current diagnostic methods.

Cardiac AmyloidosisAL AmyloidosisATTR Amyloidosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Alpelisib for Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP)

We are studying whether alpelisib can improve adaptive behavior and overall health in children and adults with MCAP. The trial will also assess the safety and effects of the treatment on brain and spinal cord health.

PIK3CA Related Overgrowth SpectrumMegalencephaly-Capillary Malformation-Polymicrogyria Syndrome>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurologyPediatrics

Hydrochlorothiazide for Polycystic Kidney Disease Patients

We are studying whether adding hydrochlorothiazide to tolvaptan can help slow kidney function decline in people with polycystic kidney disease. This trial also looks at how this combination affects quality of life and treatment tolerability.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNephrology

Esophageal Achalasia: PPI Treatment Study

We are exploring whether routine use of a medication for acid reflux is better than using it only when needed after a procedure for esophageal achalasia. This study aims to improve treatment outcomes and quality of life for patients.

Esophageal Achalasia1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Kidney Transplant: Imlifidase for Highly Sensitized Children

We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.

Kidney Transplant Rejection>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Rheumatoid Arthritis: Abatacept vs. TNF Inhibitors

We are comparing a new treatment strategy using abatacept to the standard TNF inhibitors for patients with rheumatoid arthritis. The goal is to see which approach helps more patients achieve remission.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Diabetic Foot Infections: Contezolid Treatment Study

We are studying a new treatment called contezolid for adults with moderate to severe diabetic foot infections. The goal is to see if it is safer and more effective than the current standard treatment, linezolid.

Diabetic Foot Infection≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInfectious Diseases

Advanced Breast Cancer: RLY-2608 Treatment Study

We are testing a new treatment called RLY-2608 for individuals with advanced breast cancer and other solid tumors. This study aims to understand how safe and effective this treatment may be.

Advanced Solid Tumor with PIK3CA Mutation>2 yearsSafety phase (I)Oncology